Volume of distribution as an early predictor of vancomycin-induced AKI in critically ill patients

Main Article Content

Parisa Ghasemiyeh https://orcid.org/0000-0002-8640-5724
Afsaneh Vazin
Farid Zand
Soliman Mohammadi-Samani https://orcid.org/0000-0002-1007-1422


Vancomycin, Pharmacokinetics, TDM, Volume of distribution (Vd), Critically ill patients, AKI




Download data is not yet available.
Abstract 114 | PDF Downloads 62


1. Ghasemiyeh P, Vazin A, Zand F, et al. Pharmacokinetic assessment of vancomycin in critically ill patients and nephrotoxicity prediction using individualized pharmacokinetic parameters. Front Pharmacol. 2022 Aug 24;13: 1-14. doi: 10.3389/fphar.2022.912202.
2. Ghasemiyeh P, Vazin A, and Mohammadi-Samani S. A brief review of pharmacokinetic assessments of vancomycin in special groups of patients with altered pharmacokinetic parameters. Curr Drug Saf. 2023 Nov 1;18(4):425-439. doi: 10.2174/1574886317666220801124718.
3. Gibaldi M and Perrier D. Apparent volume of distribution. In: Pharmacokinetics. New York: Wiley Online Library; 2007. p. 199-208.
4. Beringer P. Vancomycin. In: Winter's Basic Clinical Pharmacokinetics. Philadelphia: Wolters Kluwer; 2018. p. 467-496.
5. Coté CJ, Lerman J, and Anderson BJ. Pharmacokinetics and Pharmacology of Drugs Used in Children. In: A Practice of Anesthesia for Infants and Children. Auckland, New Zealand: Elsevier; 2018. p. 482-485.
6. Vondracek SF, Teitelbaum I, and Kiser TH. Principles of kidney pharmacotherapy for the nephrologist: Core curriculum 2021. Am J Kidney Dis. 2021;78(3):442-458. doi: 10.1053/j.ajkd.2021.02.342.